Skip to main content
13260917 Canada Inc. logo

13260917 Canada Inc. — Investor Relations & Filings

Ticker · MSCL TSXV Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2020-05-16 Regulatory Filings
Country CA Canada
Listing TSXV MSCL

About 13260917 Canada Inc.

www.satellos.com

13260917 Canada Inc. is the legal predecessor of Satellos Bioscience Inc., a biotechnology company specializing in regenerative medicine for degenerative muscle diseases. The company focuses on Duchenne muscular dystrophy (DMD), utilizing a proprietary scientific approach rooted in restoring muscle stem cell function. Satellos discovered that dystrophin deficiency disrupts muscle stem cell asymmetric division, hindering natural repair. Its core product development involves small molecule therapeutics, such as SAT-3247 (in Phase 2 clinical trials), designed to modulate the AAK1 protein. This modulation aims to reactivate the body's intrinsic muscle repair mechanisms, offering a novel oral treatment strategy for patients with DMD and related conditions.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings by the CEO of iCo Therapeutics Inc. It certifies the review and fair presentation of the annual filings for the financial year ended December 31, 2019. The text is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the annual filings but does not include them. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than the actual Annual Report (10-K) or Management Discussion & Analysis (MDA). The document length is short (3085 characters), consistent with a certification letter rather than a full report.
2020-05-16 English
Annual MD&A - English.pdf
Management Reports Classification · 95% confidence The document is titled 'Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Year Ended December 31, 2019,' which clearly indicates it is an MD&A section. It discusses the company's financial condition, results, business strategy, product candidates, and forward-looking statements. The document references the consolidated financial statements and the annual information form, typical of an annual report context. The length of the document (15,000 characters) and the detailed financial and operational discussion confirm it is a substantive report, not merely an announcement or certification. Therefore, this document fits the category of Management Reports (MDA), which provide detailed explanations of financial results, business trends, and outlook, distinct from the full Annual Report (10-K) but integral to it.
2020-05-16 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Management Certification related to Form 13-502F1, which is a regulatory form submitted to the Ontario Securities Commission concerning participation fees for reporting issuers. It includes certification by an officer (Chief Financial Officer) confirming the accuracy and completeness of the information provided. The content is primarily a certification letter with financial data related to market values and fees but does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. It is not a full financial report but a regulatory filing with certification. Therefore, according to the Certification Rule and the nature of the document, it should be classified as a Regulatory Filing (RNS).
2020-05-16 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 95% confidence The document is titled as consolidated financial statements for the years ended December 31, 2019 and 2018, including balance sheets, statements of loss and comprehensive loss, changes in shareholders' equity, cash flows, and accompanying notes. It contains an independent auditor's report from PricewaterhouseCoopers LLP, which provides an opinion on the fairness of the financial statements in accordance with IFRS. The document includes detailed financial data, accounting policies, and audit responsibilities. This matches the characteristics of an Annual Report or a standalone Audit Report. However, since the document is primarily the auditor's report and the consolidated financial statements (not the full annual report including management discussion and other sections), it fits best under the category of Audit Report / Information (AR). The document length (15,000 characters) and content confirm it is not a brief announcement or a certification letter, but a full audit report with financial statements. FY 2019
2020-05-16 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 13-501F1, which is a management certification related to participation fees for reporting issuers, submitted to the Alberta Securities Commission. It includes officer certification by the CFO, Michael Liggett, confirming the accuracy of the information. The document contains no financial statements or substantive financial data analysis but is primarily a certification form related to regulatory compliance and fee calculation. It is not an annual report, interim report, earnings release, or any other financial report type. Given the nature of the document as a certification and regulatory submission, it fits best under Regulatory Filings (RNS).
2020-05-16 English
News release - English.pdf
Report Publication Announcement Classification · 95% confidence The document is a press release from iCo Therapeutics Inc. providing an update on the status of the filing of its annual financial statements and related certifications for the fiscal year ended December 31, 2019. It mentions the company will rely on a filing extension due to COVID-19 and expects to file the annual filings by May 15, 2020, but does not contain the actual annual report or financial statements. The document is short (4280 characters) and serves as an announcement about the timing of the report filing rather than the report itself. Therefore, it fits the criteria for a Report Publication Announcement (RPA) rather than an Annual Report (10-K) or other detailed financial filing.
2020-04-28 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.